Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (Fc Gamma RII-b or CD32 or FCGR2B) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (Fc Gamma RII-b or CD32 or FCGR2B) Products under Development by Stage of Development | 8 | 1 |
| Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (Fc Gamma RII-b or CD32 or FCGR2B) Products under Development by Therapy Area | 9 | 1 |
| Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (Fc Gamma RII-b or CD32 or FCGR2B) Products under Development by Indication | 10 | 1 |
| Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (Fc Gamma RII-b or CD32 or FCGR2B) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (Fc Gamma RII-b or CD32 or FCGR2B) Products under Development by Companies | 13 | 2 |
| Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (Fc Gamma RII-b or CD32 or FCGR2B) Therapeutics Assessment | 15 | 7 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 2 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (Fc Gamma RII-b or CD32 or FCGR2B) Companies Involved in Therapeutics Development | 22 | 4 |
| Baxalta Incorporated | 22 | 1 |
| BioInvent International AB | 23 | 1 |
| MacroGenics, Inc. | 24 | 1 |
| Xencor, Inc. | 25 | 1 |
| Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (Fc Gamma RII-b or CD32 or FCGR2B) Drug Profiles | 26 | 15 |
| BI-1206 Drug Profile | 26 | 2 |
| MGD-010 Drug Profile | 28 | 2 |
| Monoclonal Antibody to Agonize CD32b for Immunology Drug Profile | 30 | 1 |
| Monoclonal Antibody to Agonize CD32b for Undisclosed Indication Drug Profile | 31 | 1 |
| SM-101 Drug Profile | 32 | 3 |
| SM-201 Drug Profile | 35 | 1 |
| SM-301 Drug Profile | 36 | 1 |
| XmAb-5871 Drug Profile | 37 | 3 |
| XmAb-7195 Drug Profile | 40 | 1 |
| Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (Fc Gamma RII-b or CD32 or FCGR2B) Dormant Projects | 41 | 1 |
| Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (Fc Gamma RII-b or CD32 or FCGR2B) Featured News &Press Releases | 42 | 12 |
| Jun 10, 2016: MacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2016) | 42 | 1 |
| May 11, 2016: MacroGenics to Present MGD010 Clinical Data at EULAR 2016 | 43 | 1 |
| Mar 07, 2016: Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus | 43 | 1 |
| Nov 09, 2015: Xencor Presents Data on XmAb5871 Program at American College of Rheumatology 2015 Annual Meeting | 44 | 1 |
| Jun 26, 2015: Xencor Provides Update on Its Lead Product XmAb-5871 And Expansion of Bispecific Oncology Pipeline at R&D Day | 45 | 1 |
| Jun 26, 2015: Xencor Provides Update on XmAb-7195 And Expansion of Bispecific Oncology Pipeline at R&D Day | 45 | 1 |
| Jun 10, 2015: Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting | 46 | 1 |
| May 11, 2015: Xencor's XmAb 5871 Program to be Featured in Poster Presentation at European League Against Rheumatism (EULAR) 2015 Annual Meeting | 47 | 1 |
| Apr 14, 2015: Cancer Cell publishes data highlighting the potential of BioInvent s BI-1206 to help overcome antibody drug resistance in cancer therapy | 48 | 1 |
| Mar 16, 2015: MacroGenics Initiates Phase 1 Study of MGD010 for the Treatment of Autoimmune Disorders | 48 | 1 |
| Jan 29, 2015: Xencor Reports Top-line XmAb5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis | 49 | 1 |
| Jan 29, 2015: Xencor Reports XmAb7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers | 50 | 1 |
| Jan 20, 2015: BioInvent s BI-1206 antibody to enter collaborative Phase l/ll trial funded and conducted by Cancer Research UK, CRT and LLR | 51 | 1 |
| Sep 09, 2014: SuppreMol's clinical data in SLE for its lead product SM101 accepted for presentation at the 2014 ACR / ARHP Annual Meeting in Boston | 52 | 1 |
| May 28, 2014: Xencor Initiates Phase 1 Study of XmAb7195 for Asthma | 53 | 1 |
| Appendix | 54 | 2 |
| Methodology | 54 | 1 |
| Coverage | 54 | 1 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 54 | 1 |
| Contact Us | 54 | 1 |
| Disclaimer | 55 | 1 |